Get Access to Niraparib in India

Niraparib belongs to the class of drugs that come under PARP inhibitors classification. This drug is recommended in cases of recurrent and advanced Ovarian Cancers. These conditions are further specified as recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer types. Niraparib is an oral drug known by its trade name Zejula. It is the trademark product of Tesaro, commercially available as Zejula 100mg capsules. Niraparib is an FDA approved oral medication for patients experiencing complete or partial response after platinum based treatment regimen. Recently the FDA has also approved this medication for the maintenance treatment.

Niraparib in India is an option given to the patients through import possibilities. Medical Oncologists treating Ovarian Cancer Patients often prescribe drugs like Zejula in India. Going by the clinical trial outcomes and available data, this may be considered as the drug of choice in specific settings. Patients always have the choice to consider using medications that are not available in India based on their treating physician’s recommendations. It is expected to prolong survival and benefit in terms of better quality of life.

Zejula 100mg capsules are available in a pack of 90 capsules. If your dosage is 300mg per day, one pack would be adequate for a month. Your doctor may reduce the dosage to 200mg or even 100mg per day and you can plan to use it with other medications. Treatment on Niraparib can be continued as long as the patient is tolerating without disease progression